Breaks Categories: News

MondayMar 02, 2020 1:43 pm

NetworkNewsBreaks – Lonestar Resources US Inc. (NASDAQ: LONE) Featured in ROTH Equity Research Report

Lonestar Resources US Inc. (NASDAQ: LONE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “LONE reported proved reserves as of 12/31/2019 of 100.6 million BOE, an 8% increase over the 93.4 million BOE as of 12/31/2018. LONE booked 13.9 million BOE from its successful drilling program and 5.6 million BOE of positive revisions from better than expected well performance. LONE’s SEC PV10% was $961 million, significantly higher that LONE’s recent enterprise value of $530 million.” To request access to the full report, visit http://nnw.fm/DXCr3 About Lonestar Resources US Inc. Lonestar is…

Continue Reading

MondayMar 02, 2020 1:38 pm

NetworkNewsBreaks – MagnaChip Semiconductor Corp. (NYSE: MX) Featured in ROTH Equity Research Report

MagnaChip Semiconductor Corp. (NYSE: MX) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We believe MX represents an investment opportunity as a differentiated display driver and power semiconductor vendor benefiting from improving design win momentum. Above seasonal guidance reflects solid OLED product ramp coupled with continued foundry momentum. The on-going foundry recovery increases our confidence in the market value of the asset as MX progresses in its foundry review process. We maintain our Buy rating.” To request access to the full report, visit http://nnw.fm/DXCr3 About MagnaChip Semiconductor Corp. MagnaChip is a…

Continue Reading

MondayMar 02, 2020 1:32 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Featured in ROTH Equity Research Report

Cellectar Biosciences, Inc. (NASDAQ: CLRB) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Yesterday, CLRB reported clinical results from two hematological malignancy trials, notably demonstrating robust ORR (100% ORR in LPL/WM; 43% ORR in MM at highest dose) and a 100% DCR in all patients After further data analyses over 2020, CLRB will pick a lead indication (MM or LPL/WM), and likely begin a pivotal trial in 4Q20. We view the unfavorable share price response as totally unwarranted, especially given the differentiated potency and safety shown. We reiterate our Buy and…

Continue Reading

MondayMar 02, 2020 1:25 pm

NetworkNewsBreaks – Torchlight Energy Resources, Inc. (NASDAQ: TRCH) Featured in ROTH Equity Research Report

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “TRCH announced that it has measured substantial initial potential oil and gas production from the recently drilled and completed Cactus A35 #1H well. To date, the peak 24-hour production rates are 15 BO per day and 110 Mcf per day or 33 BOE per day. TRCH announced that equating this to a 10,000-foot lateral, the Cactus well results can be extrapolated to potentially 1,500 BO per day and 11,000 Mcf per day, or 3,300 BOE per day.”…

Continue Reading

MondayMar 02, 2020 1:18 pm

NetworkNewsBreaks – ShotSpotter, Inc. (NASDAQ: SSTI) Featured in ROTH Equity Research Report

ShotSpotter, Inc. (NASDAQ: SSTI) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “SSTI's 4Q19 revenues and adjusted EBITDA both surpassed our forecasts, reversing 3Q19's downside performances. Pro forma EPS was sharply ahead, even backing out the benefit of a partially reversed expense accrual. Net coverage miles added were 34 with not attrition, its best performance since 3Q18. With 2020 guidance reiterated and appearing incrementally easier to achieve, we are increasing our price target to $39.00 to reflect its higher profitability and faster growth. We reiterate our Buy rating.” To request access…

Continue Reading

MondayMar 02, 2020 1:08 pm

NetworkNewsBreaks – The Hackett Group Inc. (NASDAQ: HCKT) Featured in ROTH Equity Research Report

The Hackett Group Inc. (NASDAQ: HCKT) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Trading for 9.3x 2020 estimated EBITDA and 14x pro forma EPS, we believe the risk-reward profile is attractive for HCKT shares. We see strength in HCKT's U.S. business and diminishing headwinds from on-premise and International as promising for a much improved growth profile in 2H20. Continued strengthening of cloud-based projects, with greater breadth and size is particularly encouraging. Additional IPaaS pilots could materialize this year, which serve as a potential catalyst for shares.” To request access to…

Continue Reading

MondayMar 02, 2020 12:59 pm

NetworkNewsBreaks – Arcus Biosciences, Inc. (NYSE: RCUS) Featured in Mizuho Securities Research Report

Arcus Biosciences, Inc. (NYSE: RCUS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We see Taiho's option to exercise zimberelimab (AB122) for development in Japan and other Asian territories (excluding China), disclosed this morning, as a validating event for this candidate, and highlights the strategic value of combining proprietary candidates such as AB928, already licensed by Taiho, with an own checkpoint inhibitor. With the in-licensing of zimberelimab we see the opportunity for Taiho to exercise additional licenses such as AB680 (CD73) and AB154 (TIGIT). We continue to believe that 2020 will…

Continue Reading

MondayMar 02, 2020 12:38 pm

NetworkNewsBreaks – Lipocine Inc. (NASDAQ: LPCN) Secures $6 Million in Registered Direct

Lipocine (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, has closed a sale of 10,084,034 Class A Units with certain institutional investors. According to the update, Lipocine secured gross proceeds of approximately $6 million from the offering, which it intends to use for working capital and general corporate purposes. Each of the units were sold at an offering price of $0.595, with each Class A Unit consisting of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $0.53 per share of…

Continue Reading

MondayMar 02, 2020 12:19 pm

NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Proposed Acquisition Further Positions it to Aid Efforts to Accelerate Discovery of New Anti-Cancers, Anti-Virals and Vaccines

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today provided an update on its proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine. According to the update, this move further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines. The acquisition will provide POAI with QM’s exclusively licensed, proven machine learning framework (“CoRE”), developed at CMU. CoRE, a predictive model-building platform for drug screening and optimization campaigns, uses hybrid machine learning…

Continue Reading

MondayMar 02, 2020 11:53 am

NetworkNewsBreaks – Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) Reaches New Production Milestone at Asphalt Ridge Facility

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), an integrated oil ‎company focused on the development and implementation of its proprietary oil-‎extraction and remediation technologies, today announced that its ‎Asphalt Ridge facility located in Vernal, Utah, since re-commencement ‎on February 19, 2020, has produced approximately 1,900 barrels of oil thus achieving an average ‎daily production rate of over 300 bbls/day on a continuous basis. This comes after a scheduled ‎temporary maintenance shutdown in January 2020, during which the team made various adjustments and completed installation of critical ‎additional equipment. Valkor Engineering also used this time to run a testing ‎regimen on the…

Continue Reading